Jeffrey Matous

Updated results of JNJ-5322, a next-generation BCMA x GPRC5D x CD3 trispecific antibody, in patients with relapsed/refractory multiple myeloma

Rakesh Popat, Amrita Y. Krishnan, Martin Kaiser, Jeffrey Matous et autres

Talquetamab with pomalidomide in patients with relapsed/refractory multiple myeloma (RRMM) : updated safety/efficacy from MonumenTAL-2

Kevin Boyd, Hang Quach, Aurore Perrot, Jeffrey Matous et autres

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash et autres

BACKGROUND: Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1 study showed promising efficacy with dual-antigen targeting of myeloma with talquetamab (anti-G protein-coupled receptor family …

us, es, il, au, ca, kr, jp, nl, br, gb (code pays fourni par la source)

Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant

Ryan T. Woodall, Alexander Pozhitkov, Azra Borogovac, Theophilus Tandoh et autres

Abstract Introduction: Daratumumab, a CD38-targeted monoclonal antibody, is a highly effective therapy in multiple myeloma. Beyond its anti-myeloma effects, it has broad interactions with other CD38+ immune cell populations leading to complex immunomodulatory effects (Viola, et al. Leukemia 2021). We hypothesized that …

us, gb (code pays fourni par la source)

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Hang Quach, Aurore Perrot, Jeffrey Matous, Noa Biran et autres

Abstract Introduction: Talquetamab (Tal) is the first G protein–coupled receptor class C group 5 member D (GPRC5D) × CD3 bispecific antibody (BsAb) approved for treatment of patients with relapsed/refractory multiple myeloma (RRMM). Pomalidomide (Pom) is an established immunomodulatory drug with direct on-tumor …

au, fr, us, nl, be, gb, es (code pays fourni par la source)

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Saad Z. Usmani, Shaji Kumar, María‐Victoria Mateos, J Christine Ye et autres

Abstract Introduction: Patients (pts) with soft tissue plasmacytomas noncontiguous with bone (true extramedullary disease [EMD]) have poor outcomes with standard therapies shown by low overall response rates (ORRs), which are not durable. Talquetamab (Tal; anti-GPRC5D×CD3) and teclistamab (Tec; anti-BCMA×CD3) are first-in-class bispecific …

us, es, il, au, ca, kr, jp, nl, br, gb (code pays fourni par la source)

Phase 2 Study of Talquetamab (Tal) + Teclistamab (Tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Extramedullary Disease (EMD): RedirecTT-1

Saad Z. Usmani, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash et autres

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Binod Dhakal, Andrew Yee, Paul Richardson, Sikander Ailawadhi et autres

POSTER: MM-906 First-in-Human Study of JNJ-79635322 (JNJ-5322), a Novel Next-Generation Trispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Phase 1 Results

Hans C. Lee, Rakesh Popat, Cyrille Touzeau, Aurore Perrot et autres

MM-906: First-in-Human Study of JNJ-79635322 (JNJ-5322), a Novel Next-Generation Trispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Phase 1 Results

Hans C. Lee, Rakesh Popat, Cyrille Touzeau, Aurore Perrot et autres

us, gb, fr, be, es, nl (code pays fourni par la source)

ORAL ABSTRACT: MM-906 First-in-Human Study of JNJ-79635322 (JNJ-5322), a Novel Next-Generation Trispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Phase 1 Results

Hans C. Lee, Rakesh Popat, Cyrille Touzeau, Aurore Perrot et autres

us, gb, fr, be, es, nl, jp (code pays fourni par la source)

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.

Niels W.C.J. van de Donk, Gala Vega, Aurore Perrot, Sébastien Anguille et autres

7505 Background: Bispecific antibodies (BsAbs) have begun to transform outcomes in MM. Emerging data suggest that targeting two MM antigens with T-cell redirection may overcome tumor heterogeneity and acquired resistance to further improve clinical outcomes. JNJ-5322 is a next-generation TsAb dually targeting …

nl, es, fr, be, gb, us (code pays fourni par la source)